Table 1. Comparison of baseline characteristics of patients with stage 4 colorectal cancer who received second and subsequent line of treatment versus no second-line therapy.

Variables	Total N=264 (%)	Group A*N=144 (%)	Group B*N=120 (%)	P value
Median age (IQR)	62 [53–72]	60 [52–69]	67 [59–74]	<0.001
Age >70	86 [33]	36 [25]	50 [42]	0.005
Male	162 [61]	87 [60]	75 [63]	0.80
WHO performance status				0.09
0	101 [38]	62 [43]	39 [33]
1	163 [62]	82 [57]	81 [67]
Charlson score	9.0±1.3	8.7±1.3	9.3±1.27	<0.001
Median distance to travel (km) (IQR)	64.4 [4.8–166]	60.0 [4.7–144]	88.1 [4.8–189]	0.58
Distance ≥100 km	113 [43]	54 [38]	59 [49]	0.06
Mean albumin g/L	33.8±6.6	34.1±6.1	33.4±7.1	0.40
Mean alkaline phosphatase /L	184±203	195±228	171±168	0.31
Mean bilirubin umol/L	12.4±15.7	13.0±17.7	11.7±13.1	0.49
Mean CEA	684±3603	494±2195	912±4776	0.37
Mean BUN	7.2±3.1	5.2±3.7	9.4±4.6	0.32
Mean hemoglobin g/L	124±16.6	125±17.2	124.4±15.9	0.67
Mean WBC	9.1±7.08	8.9±2.8	9.3±10	0.67
Extra-hepatic disease	138 [52]	83 [58]	55 [46]	0.06
Liver metastases	206 [78]	110 [76]	96 [80]	0.55
Stage IVB	112 [42]	69 [48]	43 [36]	0.06
Received radiation	63 [24]	38 [26]	25 [21]	0.31
Symptomatic primary tumor	101 [38]	52 [36]	49 [41]	0.44

Group A*, patients who were treated with second- or third-line therapy; Group B*, patients who did not receive second line treatment; ±, standard deviation. IQR, interquartile range; WHO, World Health Organization; CEA, carcinoembryonic antigen; BUN, blood urea nitrogen; WBC, white blood cell.